Concepedia

<i>ESR1</i> Promoter Hypermethylation Does Not Predict Atypia in RPFNA nor Persistent Atypia after 12 Months Tamoxifen Chemoprevention

Joseph C. Baker, Julie H. Ostrander, Siya Lem, Gloria Broadwater, Gregory R. Bean, Nicholas C. D’Amato, Vanessa Goldenberg, Craig Rowell, Catherine Ibarra-Drendall, Tracey Grant,

Cancer Epidemiology Biomarkers & Prevention · 2008 · 12 citations · 46 references

Open access

Abstract

Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.

References

46

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham et al. · JNCI Journal of the National Cancer Institute · 1998 · 5.5K citations · Full text

Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma

James G. Herman, Asad Umar, Kornélia Polyák et al. · Proceedings of the National Academy of Sciences · 1998 · 1.9K citations · Full text

Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer

C. Kent Osborne, V J Bardou, Torsten Hopp et al. · JNCI Journal of the National Cancer Institute · 2003 · 778 citations

Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

Zeruesenay Desta, Bryan A. Ward, Nadia Soukhova et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 641 citations

Biallelic inactivation of <i> hMLH <i>1</i> </i> by epigenetic gene silencing, a novel mechanism causing human MSI cancers

Martina Veigl, Lakshmi Kasturi, Joseph Olechnowicz et al. · Proceedings of the National Academy of Sciences · 1998 · 630 citations · Full text